Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Dabigatran After Enoxaparin Switch
NCT02171559Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2008
- Primary completion
- Sep 2008
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of dabigatran in venous thromboembolism (VTE) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from 0 to infinity up to 48 hours, Maximum plasma concentration up to 48 hours and 2 more. Started Aug 2008; status: completed.
02
Drugs
dabigatran
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT02171559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171559.